FAAH/MAGL-IN-2 

FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and MAGL inhibitor with IC₅₀s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment^[1].

IC₅₀: 11 nM (FAAH); 36 nM (MAGL)^[1]

FAAH/MAGL-IN-2 (compound 14) (1, 3, 10, 30, 100 μM) shows potent neuroprotection effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FAAH/MAGL-IN-2 (10 mg/kg) has the potential to produce a significant anti-nociceptive effect without affecting of motor coordination and locomotor activity^[1].
FAAH/MAGL-IN-2 (5, 10, 20 mg/kg) has the potential to treat neuropathic pain without causing locomotion impairment^[1].
FAAH/MAGL-IN-2 (2000 mg/kg; p.o.; female rats) shows well tolerated and safe up to 2000 mg/kg in the oral dose and did not alter the liver enzymes activity^[1].
FAAH/MAGL-IN-2 (20 mg/kg; p.o.) shows a good absorption behavior after oral administration^[1].
Pharmacokinetic Parameters of JAK1/TYK2-IN-2 in 200–250 g, male Wistar rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

386.25

C₁₅H₁₃Cl₂N₃O₃S

2765077-82-3

O=C(N/N=C\C1=C(Cl)C=CC=C1Cl)NC2=CC=C(S(=O)(C)=O)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jaiswal S, et al. Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones. Bioorg Med Chem. 2022; 60:116698.  [Content Brief]